China hits Swiss pharma company with RPM fine
Credit: shutterstock/vipman
China’s antitrust authority has fined the local subsidiary of Swiss pharmaceutical company Geistlich Pharma €1.3 million for dictating resale prices for a pair of products used in dental implants over a 12-year period.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Subscribe now